ClinicalTrials.gg
CompletedNCT05308953Updated Jan 10, 2024

A Phase I Safety Study of NVG-291 in Healthy Adults

A Phase 1 interventional study of NVG-291 and Placebo in Spinal Cord Injury, sponsored by NervGen Pharma. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by NervGen Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled May 2021, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Spinal Cord Injuries with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Spinal Cord Injuries · Australia.

Enrollment
6th of 15
74 · median 60
Started
2021
with 1 other
Phase 1
2 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
NervGen Pharma

Among the 17 studies in Spinal Cord Injuries with a site in Australia, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 15th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 17 studies in Spinal Cord Injuries with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Spinal Cord Injuries with a site in Australia, or all of them as a file.
02

Study summary

This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded), placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily in healthy female participants. The trial is split into three parts, starting with Part 1 (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and premenopausal females). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Parts 2 and 3, participants receive 1 dose every day for 14 days.

03

Conditions studied

  • Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects between 18 and 65 years old.
  2. between 18 and 33 kg/m2, inclusive, and a total body weight > 50 kg.
  3. All laboratory values must be within normal limits or any abnormalities deemed not .
  4. All subjects must be willing to abstain from sexual intercourse or to use adequate during the study and for an additional 120 days after the follow-up visit.
  5. Subjects must not donate ova or sperm during the study and for an additional 120 days after the follow-up visit
  6. Subjects must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.
  7. Subjects must provide written .

Exclusion criteria

Exclusion Criteria:

  1. For premenopausal female subjects: Irregular menstrual cycles; Amenorrhea; or Abnormal vaginal bleeding
  2. A history (within the past year) or presence of a infectious disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality.
  3. Blood pressure > 160/95 at screening or on Day -1.
  4. Any active or uncontrolled infections or other medical condition or circumstance that could interfere with the subject's participation in the study.
  5. History of allergic reaction to mannitol.
  6. Presence of a tattoo, piercing, scar, or other dermatologic abnormality at the injection site (abdomen), that might interfere with the ability to assess injection site reactions
  7. a significant history of atopic dermatitis as an adult, or history of severe allergic reaction to injections.
  8. > 1.4 or PTT > 50 or \<50x10\^3/µL at screening or on Day -1.
  9. History of regular alcohol consumption exceeding 10 units/week (1 unit = 83 mL of 12% wine) within 6 months of screening.
  10. Test positive for use of drugs or alcohol at screening.
  11. Positive , , or test at screening.
  12. Blood or plasma donation within 1 week prior to Day -1.
  13. Receipt of an drug within 30 days or five half-lives of the drug (whichever is longer) prior to Day -1.
  14. Prior participation in this trial.
  15. Female subjects who are breastfeeding or who have a positive pregnancy test at screening or Day -1.
  16. History of any condition that might impair the subject's ability to understand or to comply with the requirements of the study or to provide .
  17. Receipt of a COVID-19 vaccination within 3 weeks prior to Day -1
  18. Subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior or endorsing items 4 or 5 on the Columbia-Suicide Severity Rating Scale at screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    NVG-291 SAD

    Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.

    Drug: NVG-291 · Other: Placebo

  • Experimental
    NVG-291 MAD

    Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.

    Drug: NVG-291 · Other: Placebo

  • Experimental
    NVG-291 MAD - Males and Premenopausal Females

    Participants will receive 1 dose daily for for 14 consecutive days. The dose maximum daily dose in Part 3 will not exceed the maximum daily dose tolerated in either Part 1 or 2.

    Drug: NVG-291 · Other: Placebo

Interventions

  • NVG-291 is a drug injected under the skin (subcutaneous).

  • OtherPlacebo

    Salt water is being used as a placebo and will be injected under the skin (subcutaneous).

06

What researchers measure

Primary outcomes

  1. Adverse Events

    number and frequency of adverse events

    Time frame: Assessed through 7 days following the last dose of study drug

Secondary outcomes

  1. Pharmacokinetic analysis (plasma)

    measure of concentration of drug in blood plasma

    Time frame: Assessed on Day 1 (SAD and MAD) and Day 14 (MAD only)

  2. Immunogenicity analysis

    number of participants with confirmed and titer results for the presence of anti-drug antibodies

    Time frame: Assessed on Day 1 (SAD and MAD), Day 8 (SAD and MAD) and Day 21 (MAD only)

07

Study locations

1 site
  • Nucleus Networks
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2023, 24 months.

Of 51 phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Apr 4, 2022
StartActual
May 6, 2021
Primary completionActual
Jun 4, 2023
CompletionActual
Jul 3, 2023
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05308953
Lead sponsor
NervGen Pharma
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
May 6, 2021
Primary completion
Jun 4, 2023
Completion
Jul 3, 2023
Last update
Jan 10, 2024

Study contacts

Daniel Miko, MD
study director · CMO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVG-291

Start the discussion